178 related articles for article (PubMed ID: 17335811)
21. Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats.
Billet F; Costentin J; Dourmap N
Exp Neurol; 2012 Aug; 236(2):339-50. PubMed ID: 22575599
[TBL] [Abstract][Full Text] [Related]
22. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
[TBL] [Abstract][Full Text] [Related]
23. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Hamadjida A; Nuara SG; Kwan C; Frouni I; Bédard D; Gourdon JC; Huot P
Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2157-2164. PubMed ID: 32621059
[TBL] [Abstract][Full Text] [Related]
24. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
Morissette M; Samadi P; Hadj Tahar A; Bélanger N; Di Paolo T
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):446-54. PubMed ID: 20026151
[TBL] [Abstract][Full Text] [Related]
25. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
[TBL] [Abstract][Full Text] [Related]
26. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
[TBL] [Abstract][Full Text] [Related]
27. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
Samadi P; Grégoire L; Hadj Tahar A; Di Paolo T; Rouillard C; Bédard PJ
Neuropharmacology; 2005 Aug; 49(2):165-73. PubMed ID: 15996565
[TBL] [Abstract][Full Text] [Related]
28. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
Thornton E; Hassall MM; Corrigan F; Vink R
Parkinsonism Relat Disord; 2014 May; 20(5):508-13. PubMed ID: 24637127
[TBL] [Abstract][Full Text] [Related]
29. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.
Morissette M; Goulet M; Soghomonian JJ; Blanchet PJ; Calon F; Bédard PJ; Di Paolo T
Brain Res Mol Brain Res; 1997 Oct; 49(1-2):55-62. PubMed ID: 9387863
[TBL] [Abstract][Full Text] [Related]
30. The kappa opioid agonist U50,488 potentiates 6-hydroxydopamine-induced neurotoxicity on dopaminergic neurons.
Marin C; Bové J; Serrats J; Cortés R; Mengod G; Tolosa E
Exp Neurol; 2005 Jan; 191(1):41-52. PubMed ID: 15589511
[TBL] [Abstract][Full Text] [Related]
31. Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
Huang LZ; Campos C; Ly J; Ivy Carroll F; Quik M
Neuropharmacology; 2011 May; 60(6):861-8. PubMed ID: 21232546
[TBL] [Abstract][Full Text] [Related]
32. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
Ikeda K; Yoshikawa S; Kurokawa T; Yuzawa N; Nakao K; Mochizuki H
Eur J Pharmacol; 2009 Oct; 620(1-3):42-8. PubMed ID: 19686730
[TBL] [Abstract][Full Text] [Related]
33. Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice.
Quik M; Park KM; Hrachova M; Mallela A; Huang LZ; McIntosh JM; Grady SR
Neuropharmacology; 2012 Sep; 63(3):450-9. PubMed ID: 22579614
[TBL] [Abstract][Full Text] [Related]
34. Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Gerlach M; Bartoszyk GD; Riederer P; Dean O; van den Buuse M
J Neural Transm (Vienna); 2011 Dec; 118(12):1733-42. PubMed ID: 21253782
[TBL] [Abstract][Full Text] [Related]
35. The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.
Bordia T; McIntosh JM; Quik M
J Neurochem; 2013 Apr; 125(2):291-302. PubMed ID: 23373725
[TBL] [Abstract][Full Text] [Related]
36. L-type Ca2+ channel modulation by dihydropyridines potentiates kappa-opioid receptor agonist induced acute analgesia and inhibits development of tolerance in rats.
Gullapalli S; Ramarao P
Neuropharmacology; 2002 Mar; 42(4):467-75. PubMed ID: 11955518
[TBL] [Abstract][Full Text] [Related]
37. Anti-arrhythmic effect of kappa-opioid receptor stimulation in the perfused rat heart: involvement of a cAMP-dependent pathway.
Yu XC; Wang HX; Pei JM; Wong TM
J Mol Cell Cardiol; 1999 Oct; 31(10):1809-19. PubMed ID: 10525419
[TBL] [Abstract][Full Text] [Related]
38. Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias.
Samadi P; Grégoire L; Morissette M; Calon F; Hadj Tahar A; Bélanger N; Dridi M; Bédard PJ; Di Paolo T
Neuropharmacology; 2008 Feb; 54(2):258-68. PubMed ID: 18001807
[TBL] [Abstract][Full Text] [Related]
39. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
Henry B; Fox SH; Peggs D; Crossman AR; Brotchie JM
Mov Disord; 1999 Sep; 14(5):744-53. PubMed ID: 10495035
[TBL] [Abstract][Full Text] [Related]
40. Stimulation of kappa-opioid receptor reduces isoprenaline-induced cardiac hypertrophy and fibrosis.
Yin W; Zhang P; Huang JH; Zhang QY; Fan R; Li J; Zhou JJ; Hu YZ; Guo HT; Zhang SM; Wang YM; Kaye AD; Gu CH; Liu JC; Cheng L; Cui Q; Yi DH; Pei JM
Eur J Pharmacol; 2009 Apr; 607(1-3):135-42. PubMed ID: 19233160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
